A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer

QR Code

A Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast Cancer

Abstract Doxorubicin forms the basis of chemotherapy regimens for several malignancies, including triple negative breast cancer (TNBC). Here, we present a coupled experimental/modeling approach to establish an in vitro pharmacokinetic/pharmacodynamic model to describe how the concentration and durat...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Matthew T. McKenna, Jared A. Weis, Stephanie L. Barnes, Darren R. Tyson, Michael I. Miga, Vito Quaranta, Thomas E. Yankeelov
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2017
Sujets:	Medicine R Science Q
Accès en ligne:	https://doaj.org/article/e8a68c155b6c4782a3384e08511f52ab
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Activity of docetaxel, carboplatin, and doxorubicin in patient-derived triple-negative breast cancer xenografts
par: Miguel Martin, et autres
Publié: (2021)

The paracrine effects of adipocytes on lipid metabolism in doxorubicin-treated triple negative breast cancer cells
par: Ilze Mentoor, et autres
Publié: (2021)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
par: Julia Foldi, et autres
Publié: (2021)

Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy
par: Abramson RG, et autres
Publié: (2012)

Therapeutic Effect of Doxorubicin-Chlorin E6-Loaded Mesoporous Silica Nanoparticles Combined with Ultrasound on Triple-Negative Breast Cancer
par: Xu P, et autres
Publié: (2020)

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells
par: Swanner J, et autres
Publié: (2015)

A triple negative breast cancer: what it is not!
par: Katakkar SB
Publié: (2012)

Triple negative breast cancer: an Indian perspective
par: Akhtar M, et autres
Publié: (2015)

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.
par: Wen-Hung Kuo, et autres
Publié: (2012)

BRCA2 mutations and triple-negative breast cancer.
par: Peter Meyer, et autres
Publié: (2012)

Triple-negative breast cancer: treatment challenges and solutions
par: Collignon J, et autres
Publié: (2016)

Opportunities for metastatic triple negative breast cancer therapy
par: Inna P. Ganshina, et autres
Publié: (2021)

Antiangiogenic therapy for breast cancer with triple negative phenotype
par: Inna P. Ganshina, et autres
Publié: (2021)

Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan.
par: Lee H Chen, et autres
Publié: (2011)

Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures.
par: Thomas Karn, et autres
Publié: (2011)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
par: Marina K. Ibragimova, et autres
Publié: (2021)

Molecular heterogeneity in adjacent cells in triple-negative breast cancer
par: Huebschman ML, et autres
Publié: (2015)

Protein truncating variants in FANCM and risk for ER-negative/triple negative breast cancer
par: Paolo Peterlongo, et autres
Publié: (2021)

Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
par: Leisha A Emens, et autres
Publié: (2021)

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer
par: Ivana Zagorac, et autres
Publié: (2018)

In vitro to Clinical Translation of Combinatorial Effects of Doxorubicin and Abemaciclib in Rb-Positive Triple Negative Breast Cancer: A Systems-Based Pharmacokinetic/Pharmacodynamic Modeling Approach
par: Fleisher B, et autres
Publié: (2021)

Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
par: Vanessa Y. C. Sung, et autres
Publié: (2021)

Correction: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
Publié: (2021)

Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment
par: L. E. Anselmino, et autres
Publié: (2021)

A new immunochemical strategy for triple-negative breast cancer therapy
par: Chih-Wei Lin, et autres
Publié: (2021)

Peptide density targets and impedes triple negative breast cancer metastasis
par: Daxing Liu, et autres
Publié: (2018)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
par: Fleisher B, et autres
Publié: (2016)

Triple-Negative Breast Cancer Histological Subtypes with a Favourable Prognosis
par: Gábor Cserni, et autres
Publié: (2021)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
par: Inna P. Ganshina, et autres
Publié: (2021)

Non-Coding RNAs Associated With Radioresistance in Triple-Negative Breast Cancer
par: Alberto Aranza-Martínez, et autres
Publié: (2021)

An experimental-mathematical approach to predict tumor cell growth as a function of glucose availability in breast cancer cell lines.
par: Jianchen Yang, et autres
Publié: (2021)

Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer
par: Anna E. M. Bastiaansen, et autres
Publié: (2020)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
par: Bingqing Xia, et autres
Publié: (2021)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
par: Peng Su, et autres
Publié: (2021)

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients.
par: Katsuhiro Yoshikawa, et autres
Publié: (2021)

Expression of LGR5 in mammary myoepithelial cells and in triple-negative breast cancers
par: Hyun Ju Lee, et autres
Publié: (2021)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
par: Corey Speers, et autres
Publié: (2017)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
par: da Silva JL, et autres
Publié: (2021)

Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment
par: Bowen Gao, et autres
Publié: (2021)

Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling
par: Radhakrishnan Vishnubalaji, et autres
Publié: (2021)